Hospital Injectable Products · LP-185
Furosemide Injection
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-185Hospital Injectable Products
- Generic identity
- FurosemideInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-185
- Generic identity
- Furosemide
- Presentation
- Injection
- Catalogue strength
- 10 mg/mL
- Catalogue pack
- Ampoule 2 mL; carton 10 ampoules
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Furosemide.
- Dosage form: injection.
- Catalogue strength / concentration: 10 mg/mL.
- Catalogue pack: Ampoule 2 mL; carton 10 ampoules.
- Catalogue category: Hospital Injectable Products.
Layer 02 · Unresolved product-specific fields
- Exact sterile formulation, pH, excipients, preservative status and particulate/endotoxin specifications.
- Approved route(s) and route-specific administration rate, dilution/compatibility and monitoring instructions for the exact product.
- Ampoule material/closure and controlled carton/ampoule SKU evidence.
- Storage/light protection, shelf life, registration, manufacturing/sterilisation route and supply status.
Identity note
External injection references describe comparator products; they do not establish IV/IM authorisation, formulation or compatibility for LP-185.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 10 mg/mL | Injection | — | Ampoule 2 mL; carton 10 ampoules | Concentration and container size are preserved independently; route, total-dose instructions, dilution and compatibility are not inferred. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Furosemide is a loop diuretic that increases renal excretion of sodium and water. Injectable formulations are used when the clinical setting calls for a parenteral route, including selected acute fluid-overload situations or inability to use oral therapy. It is not appropriate for every swollen limb or unexplained breathlessness. The underlying cause, circulatory status and kidney function determine the clinical decision.
Clinical context and therapeutic role
Assessment includes fluid balance, blood pressure, symptoms, kidney function and electrolytes. The response to a diuretic must be interpreted alongside the disease causing fluid retention, such as cardiac, renal or hepatic illness. An injection concentration does not establish a protocol for an acute episode. This page describes ingredient-related considerations without a dosing, infusion or conversion instruction and does not confirm candidate-specific authorized indications.
Selected safety context
Excessive diuresis can cause dehydration, hypotension, electrolyte depletion and deterioration in kidney function. Hearing-related adverse effects are an important risk in certain exposure or interaction settings. Review other diuretics, nephrotoxic or ototoxic medicines, lithium and relevant cardiovascular therapies. Severe dizziness, reduced urine output, muscle weakness or hearing changes require assessment. Monitoring should be matched to the patient’s clinical condition and treatment response.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The source describes injectable solution in ampoules. Verify the exact concentration, total amount, pH-related compatibility and authorized routes. A matching milligram amount does not establish equivalence between oral and parenteral administration.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Confirm the fluid-management indication, circulatory status, renal function, electrolytes and interactions. Use product-specific information with appropriate clinical and laboratory monitoring.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Sterile finished-product specification and quantitative formulation.
Approved injectable label/leaflet with exact route, administration, dilution/compatibility and monitoring instructions.
Ampoule/container-closure and sterile-manufacturing/sterilisation evidence.
Registration/market-status evidence for the exact injectable presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07c checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: Furosemide — ingredient/formulation referenceArchived source classification: government-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-185.
Professional enquiries
Request product-specific evidence for LP-185.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.